{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:17Z","timestamp":1791497597722,"version":"4.3.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> QT prolongation and torsades de pointes pose a major concern for cardiologists and oncologists. Although cancer patients are suspected to have prolonged QT intervals, this has not been investigated in a large population. The purpose of this study was to analyze the QT interval distribution in a cancer population and compare it to a non-cancer population in the same institution.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The study was a retrospective review of 82,410 ECGs performed in cancer patients (51.8% women and 48.2% men) and 775 ECGs performed in normal stem cell donors (47.9% women and 52.1% men) from January 2009 to December 2013 at the University of Texas MD Anderson Cancer Center. Pharmacy prescription data was also collected and analyzed during the same time period. Correction of the QT interval for the heart rate was performed using the Bazett and Fridericia formulas.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> After QT correction for heart rate by the Fridericia formula (QTcF), the mean and 99% percentile QTc for cancer patients were 414 and 473 ms, respectively. These were significantly longer than the normal stem cell donors, 407 and 458 ms, <jats:italic>p<\/jats:italic> &amp;lt; 0.001, respectively. Among the cancer patients, the QTc was longer in the inpatient setting when compared to both outpatient and emergency center areas. The most commonly prescribed QT prolonging medications identified were ondansetron and methadone.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study demonstrates significantly longer QTc intervals in cancer patients, especially in the inpatient setting. Frequently prescribed QT prolonging medications such as antiemetics and analgesics may have a causative role in QT prolongation seen in our cancer hospital.<\/jats:p>","DOI":"10.3389\/fcvm.2021.613625","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T04:41:55Z","timestamp":1614228115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["QT Prolongation in Cancer Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Peter","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Masha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Karimzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saamir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Hong","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijcard.2017.05.072","article-title":"Incidence of Torsade de Pointes in a tertiary hospital population","volume":"243","author":"Vandael","year":"2017","journal-title":"Int J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5603\/CJ.2012.0078","article-title":"QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature","volume":"19","author":"Lynch","year":"2012","journal-title":"Cardiol J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.1158\/1078-0432.CCR-09-0369","article-title":"A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies","volume":"15","author":"Burris","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome\u2013positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B7","first-page":"61134","volume":"70","year":"2005","journal-title":"Fed Regist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2217\/14622416.7.6.889","article-title":"Can pharmacogenetics help rescue drugs withdrawn from the market?","volume":"7","author":"Shah","year":"2006","journal-title":"Pharmacogenomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1200\/JCO.2003.99.104","article-title":"Baseline heart rate-corrected QT and eligibility for clinical trials in oncology","volume":"21","author":"Varterasian","year":"2003","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"203s","DOI":"10.1200\/jco.2005.23.16_suppl.3047","article-title":"Risk management and eligibility criteria for QTc assessment in patients with advanced cancer","volume":"23","author":"Sarapa","year":"2005","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/europace\/eut214","article-title":"Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany","volume":"16","author":"Sarganas","year":"2014","journal-title":"Europace"},{"key":"B13","doi-asserted-by":"publisher","first-page":"K70","DOI":"10.1016\/S1520-765X(01)90009-4","article-title":"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes","volume":"3","author":"Darpo","year":"2001","journal-title":"Eur Heart J Suppl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/01.CIR.97.5.493","article-title":"Ibutilide","volume":"97","author":"Murray","year":"1998","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.hrthm.2009.01.009","article-title":"Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts","volume":"6","author":"Kobza","year":"2009","journal-title":"Heart Rhythm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/clc.20208","article-title":"Assessment of QT intervals and prevalence of short QT syndrome in Japan","volume":"31","author":"Funada","year":"2008","journal-title":"Clin Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.amjcard.2006.04.035","article-title":"Distribution and prognostic significance of QT intervals in the lowest half centile in 12,012 apparently healthy persons","volume":"98","author":"Gallagher","year":"2006","journal-title":"Am J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1161\/CIRCULATIONAHA.106.676551","article-title":"Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population","volume":"116","author":"Anttonen","year":"2007","journal-title":"Circulation."},{"key":"B19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/clpt.2009.214","article-title":"Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc Interval)","volume":"87","author":"Morganroth","year":"2010","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.613625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T04:41:58Z","timestamp":1614228118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.613625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":19,"alternative-id":["10.3389\/fcvm.2021.613625"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.613625","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"613625"}}